大型多国耐多药/利福平耐药结核队列中延长使用贝达喹啉或德拉马尼时QT间期延长的频率和发生率
该前瞻性队列纳入16国2553例耐多药/利福平耐药结核患者,59%使用贝达喹啉和/或德拉马尼超过6个月;20.9%发生QT延长事件,绝大多数为1-2级,仅2.5%达到主要结局,0.5%因QT延长永久停用至少一种药物。
要点
- 贝达喹啉和/或德拉马尼使用超过6个月在较长疗程中安全,多数临床相关QT延长发生于前6个月。
- 2553例中59%使用超过6个月,20.9%发生QT延长事件,95.5%为1级或2级。
- 仅2.5%发生主要结局,0.5%因QT延长永久停用至少一种药物。
核心结论
- 贝达喹啉和/或德拉马尼使用超过6个月在较长耐多药/利福平耐药结核方案中是安全的,大多数临床相关QT延长事件发生在前6个月。
研究设计与样本
- 前瞻性队列研究,纳入16个国家2015年4月1日至2018年9月30日启动含贝达喹啉和/或德拉马尼方案治疗的耐多药/利福平耐药结核患者,共2553例,采用共享方案系统收集数据。
主要发现
- 2553例患者中59%接受贝达喹啉和/或德拉马尼治疗超过6个月。
- 579例(20.9%)发生QT延长事件,其中95.5%为1级或2级。
- 64例(2.5%)发生主要结局,仅12例(0.5%)永久停用至少一种QT延长药物。
- 首次QT延长事件的发生率在治疗前6个月最高,后续6个月期间较低。
关键数值与推荐
- 主要结局为首次临床相关QT间期延长(3级或以上)或涉及任何级别QT延长的严重不良事件。
临床怎么用
- 在规划条件下可通过心电图监测早期识别QT延长事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen and 6 months or longer for Bdq and delamanid (Dlm) in the 18-20-month longer regimen. However, lack of evidence on extended treatment using Bdq or Dlm has limited their use to 6 months. We examine the frequency and incidence of QT prolongation based on duration of Bdq and/or Dlm use in longer regimens. METHODS: We analyzed a prospective cohort of MDR/RR-TB patients from 16 countries who initiated treatment with Bdq and/or Dlm containing regimens from 1 April 2015 to 30 September 2018. Data were systematically collected using a shared protocol. The outcome of interest was the first clinically relevant prolonged QT interval (grade 3 or above) or a serious adverse event (SAE) involving prolonged QT of any grade. RESULTS: Among 2553 patients, 59% received >6 months of Bdq and/or Dlm. Of these, 579 (20.9%) patients experienced a prolonged QT event, the majority (95.5%) being grade 1 or 2. Sixty-four (2.5%) patients experienced the outcome of interest with only 12 (0.5%) having ≥1 QT prolonging drugs permanently suspended. The incidence rate of the first prolonged QT event was highest in the first six months of treatment and lower in subsequent 6-month periods. CONCLUSIONS: We demonstrate that Bdq and/or Dlm use beyond 6 months is safe in longer MDR/RR-TB regimens with most clinically relevant QT prolongation events occurring in the first 6 months. Electrocardiogram (ECG) monitoring for early identification of QT prolongating events is possible in programmatic conditions.
引用
- Khan U, Rich M, Franke MF, et al. The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort. Clin Infect Dis. 2025. PMID: 39658125. doi:10.1093/cid/ciae601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。